Epigallocatechin gallate (EGCG) regulates ferroptosis to participate in myocardial ischemia-reperfusion injury
Frontiers in Pharmacology · 20.11.2026 · 17
DOI: 10.3389/fphar.2026.1861193 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 20.11.2026. Verfasst von YangLi He und 6 weiteren Autor:innen. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hainan Province, Hainan Provincial Health and Family Planning Commission, National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
To investigate whether epigallocatechin gallate (EGCG) alleviates myocardial ischemia-reperfusion (I/R) injury via regulating ferroptosis and further elucidate the underlying mechanism.
Methods
I/R models were established in H9c2 cardiomyocytes in vitro and in rats via coronary artery ligation in vivo . Lentiviral transfection was conducted in H9c2 cardiomyocytes, and transcriptome sequencing was performed using rat myocardial tissues. Cell viability, ferroptosis-related indicators (Fe 2+ , LDH, GSH, MDA), and the expression of key proteins (SLC7A11, FTH1, GPX4, ACSL4, PHD2, HIF-1α) were detected. Myocardial injury was assessed using TTC staining, HE staining and transmission electron microscopy.
Results
In H9c2 cardiomyocytes, EGCG produced effects comparable to ferroptosis inhibitors (ferrostatin-1 (Fer-1), deferoxamine (DFO)), reversing Erastin/RSL3 - triggered cell death, enhancing cell viability and diminishing ROS and Fe 2+ accumulation. In the setting of myocardial I/R, these interventions improved cell viability, lowered MDA levels, reduced infarct size and alleviated mitochondrial injury ( P < 0.05). Consistent downregulation of SLC7A11, FTH1 and GPX4 following I/R was observed in both H9c2 cardiomyocytes with simulated I/R and rat myocardium with in vivo I/R ( P < 0.05), and treatment with EGCG, Fer-1 or DFO restored the expression of these proteins in both models. In rat myocardium, I/R upregulated ACSL4, and this elevation was suppressed by EGCG, Fer-1 and DFO. By contrast, only high-dose EGCG inhibited ACSL4 expression in H9c2 cardiomyocytes subjected to simulated I/R. Iron overload exacerbated I/R-triggered myocardial injury and ferroptosis, and EGCG pretreatment alleviated such deterioration ( P < 0.05). Mechanistically, I/R upregulated PHD2 while suppressing HIF-1α and FTH1 expression ( P < 0.05). EGCG pretreatment reversed these I/R-induced alterations, whereas PHD2 overexpression or HIF-1α knockdown abolished the cardioprotective effects of EGCG ( P < 0.05).
Conclusion
Our findings demonstrate that EGCG alleviates myocardial I/R injury and suppresses ferroptosis by tuning iron homeostasis and the PHD2/HIF-1α signalling cascade.
Förderung
- Natural Science Foundation of Hainan Province
- Hainan Provincial Health and Family Planning Commission
- National Natural Science Foundation of China
Zitieren
APA
He, Y., Zhang, J., Fang, T., Yang, Y., Zhou, J., Xie, T., & Zeng, M. (2026). Epigallocatechin gallate (EGCG) regulates ferroptosis to participate in myocardial ischemia-reperfusion injury. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1861193
Vancouver
He Y, Zhang J, Fang T, Yang Y, Zhou J, Xie T, et al. Epigallocatechin gallate (EGCG) regulates ferroptosis to participate in myocardial ischemia-reperfusion injury. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1861193
BibTeX
@article{He2026,
author = {He, YangLi and Zhang, Jianan and Fang, TuanYu and Yang, YaLi and Zhou, JinChao and Xie, Tian and Zeng, Min},
title = {Epigallocatechin gallate (EGCG) regulates ferroptosis to participate in myocardial ischemia-reperfusion injury},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1861193}
}
EUVIMED